# Cellular protection against oxidative Stress and Alzheimer’s

In a recent study I co-authored (https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70117), we gained new insights into how genetically driven changes in antioxidant defense pathways contribute to Alzheimer’s disease (AD). Our research focused on key enzymes such as **superoxide dismutase 1 (SOD1)** and **glutathione S-transferase omega 1 (GSTO1)** — both essential for cellular protection against oxidative stress.

## Genetics Meets Biochemistry: SNP rs4925 in GSTO1

Using genomic analysis, we identified a specific single nucleotide polymorphism (*SNP rs4925*) in the *GSTO1* gene that is associated with elevated GSTO1 levels in platelet samples. This genetic variant may reflect a compensatory response to increased oxidative stress — a known hallmark of AD pathology.

## SOD1 and CCS: Early Biomarkers in Disease Progression

In addition to elevated GSTO1, we observed increased levels of **SOD1**, an enzyme that converts superoxide radicals into hydrogen peroxide. Interestingly, **copper chaperone for SOD1 (CCS)** — which is critical for SOD1 activation — was already reduced in individuals with **mild cognitive impairment (MCI)**, suggesting dysregulated enzyme activity even at early disease stages.

## GPX1 and Glutathione: A System in Disbalance

We also found that **glutathione peroxidase 1 (GPX1)**, an enzyme that works in tandem with SOD1, was significantly decreased in both frontal lobe brain tissue and platelets in AD patients. These findings highlight an imbalance in the **glutathione system**, one of the body’s most important defenses against oxidative damage.

## SAM-e: A Promising Therapeutic Target

One potential therapeutic approach involves targeting the **methionine cycle**, particularly through supplementation with **S-adenosylmethionine (SAM-e)**. SAM-e is not only a universal methyl donor for epigenetic regulation but also a key precursor in the **transsulfuration pathway**, which leads to **glutathione synthesis**. Enhancing this metabolic route may help boost antioxidant capacity and offer neuroprotective effects.

## Conclusion

Our findings underscore the importance of genetic variants in regulating oxidative stress in Alzheimer’s and open the door to more personalized therapeutic strategies. Early changes in **SOD1** and **CCS** levels — detectable even in **MCI** — highlight the potential of these proteins as biomarkers and therapeutic targets. Supporting the glutathione system via **SAM-e** could represent a viable strategy to counteract oxidative damage in early neurodegeneration.

Yours,
Eduard Rappold

Note: This information is provided for educational purposes and does not substitute for professional medical advice. Always consult with healthcare providers for personalized guidance on health-related matters.

nugenis.eu/shop/

Eduard Rappold

Dr. Eduard Rappold, MSc ist ein erfahrener Forscher und Arzt, der sich seit Jahrzehnten für geriatrische PatientInnen einsetzt. In seinem Bemühen für Alzheimer-Erkrankte eine immer bessere Versorgung zu ermöglichen, wurde er 2003 mit dem Gesundheitspreis der Stadt Wien für das Ernährungszustandsmonitoring von Alzheimer-Kranken ausgezeichnet. Im Zuge seines Masterstudiums der Geriatrie hat er seine Entwicklung des Epigenetic Brain Protector wissenschaftlich fundiert und empirisch überprüft. Im September 2015 gründete er NUGENIS, ein Unternehmen, mit dem er Wissenschaft und Anwendung zusammenbringen möchte. Damit können Menschen unmittelbar von den Ergebnissen der Angewandten Epigenetik für ihre Gesundheit profitieren. Mit dem Epigenetic Brain Protector hat Dr. Eduard Rappold, MSc bereits für internationales Aufsehen gesorgt – auf der international wichtigsten Innovationsmesse, der iENA, wurde er 2015 mit einer Goldmedaille für hervorragende Leistungen zum Schutz vor Neurodegeneration ausgezeichnet. Auf den Webseiten nugenis.eu, epigenetik.at, spermidine-soyup.com und facebook.com/nugenis können Themen zur Epigenetik und Aktuelles nachgelesen werden.